StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.76−0.06 (-0.81%)

Close on Nov 18, 2026Market cap $442.34MP/E 42.3Yield –

Arvinas operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Arvinas's operating cash flow for the twelve months ending Jun 30, 2026 was -$207.00M. For fiscal 2025 it was -$273.80M. The highest annual figure on record is $559.40M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$273.80M–
FY2024Dec 31, 2024-$259.30M–
FY2023Dec 31, 2023-$347.80M–
FY2022Dec 31, 2022-$273.50M-148.9%
FY2021Dec 31, 2021$559.40M–
FY2020Dec 31, 2020-$89.70M–
FY2019Dec 31, 2019-$40.60M–
FY2018Dec 31, 2018-$16.12M-415.2%
FY2017Dec 31, 2017$5.11M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.30M–
Q1 FY2026Mar 31, 2026-$69.20M–
Q4 FY2025Dec 31, 2025-$30.40M–
Q3 FY2025Sep 30, 2025-$59.10M–
Q2 FY2025Jun 30, 2025-$95.40M-289.7%
Q1 FY2025Mar 31, 2025-$88.90M–
Q4 FY2024Dec 31, 2024-$84.10M–
Q3 FY2024Sep 30, 2024-$128.00M–
Q2 FY2024Jun 30, 2024$50.30M–
Q1 FY2024Mar 31, 2024-$97.50M–
Q4 FY2023Dec 31, 2023-$83.10M–
Q3 FY2023Sep 30, 2023-$84.80M–
Q2 FY2023Jun 30, 2023-$88.70M–
Q1 FY2023Mar 31, 2023-$91.20M–
Q4 FY2022Dec 31, 2022-$71.20M–
Q3 FY2022Sep 30, 2022-$66.60M-109.8%
Q2 FY2022Jun 30, 2022-$78.60M–
Q1 FY2022Mar 31, 2022-$57.10M–
Q4 FY2021Dec 31, 2021-$35.70M–
Q3 FY2021Sep 30, 2021$681.50M–
Q2 FY2021Jun 30, 2021-$47.40M–
Q1 FY2021Mar 31, 2021-$39.00M–
Q4 FY2020Dec 31, 2020-$28.96M–
Q3 FY2020Sep 30, 2020-$22.38M-1307.6%
Q2 FY2020Jun 30, 2020-$21.40M–
Q1 FY2020Mar 31, 2020-$16.95M–
Q4 FY2019Dec 31, 2019-$16.15M–
Q3 FY2019Sep 30, 2019$1.85M–
Q2 FY2019Jun 30, 2019-$13.57M–
Q1 FY2019Mar 31, 2019-$12.73M-166.0%
Q4 FY2018Dec 31, 2018-$12.25M-143.5%
Q3 FY2018Sep 30, 2018-$10.99M–
Q2 FY2018Jun 30, 2018-$12.18M–
Q1 FY2018Mar 31, 2018$19.30M–
Q4 FY2017Dec 31, 2017$28.16M–

More Arvinas figures

See a number that looks wrong?